Immix Biopharma AI Stock Analysis
Immix Biopharma (IMMX) AI Stock Analysis
Immix Biopharma
(NASDAQ:IMMX)
The score is held back primarily by weak financial performance (no revenue, widening losses, and rising cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting these are a strengthened balance sheet (low debt plus recent capitalization) and positive corporate catalysts (meaningful funding raise and strong interim Phase 2 results), while valuation is difficult to justify using P/E due to ongoing losses.
Immix Biopharma (IMMX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $669.03M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.49M
- Price to Earnings (P/E)
- -9.3
- Beta (1Y)
- 1.30
- Revenue Growth
- ―
- EPS Growth
- -11.21%
- Country
- US
- Employees
- 21
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Immix Biopharma Business Overview & Revenue Model
Company Description
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. The...
Immix Biopharma Financial Statement Overview
Summary
Development-stage profile with no revenue and worsening losses and cash burn (TTM net loss about -$46.3M; operating cash flow about -$44.9M). The key support is a very low-leverage balance sheet and sharply higher equity/assets by TTM, which improves financial runway but does not resolve weak operating and cash-flow performance.
Income Statement
18Very NegativeBalance Sheet
72PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -48.62M | -29.59M | -21.54M | -15.56M | -8.22M | -24.20M |
| Net Income | -46.26M | -29.44M | -21.61M | -15.43M | -8.23M | -24.38M |
Balance Sheet | ||||||
| Total Assets | 345.95M | 104.84M | 22.95M | 19.93M | 14.91M | 18.19M |
| Cash, Cash Equivalents and Short-Term Investments | 336.30M | 100.41M | 17.68M | 17.51M | 13.44M | 17.64M |
| Total Debt | 965.05K | 1.07M | 1.07M | 0 | 0 | 50.00K |
| Total Liabilities | 10.89M | 11.04M | 9.70M | 3.72M | 1.75M | 202.04K |
| Stockholders Equity | 335.06M | 93.80M | 13.25M | 16.41M | 13.16M | 17.99M |
Cash Flow | ||||||
| Free Cash Flow | -45.24M | -24.66M | -15.77M | -11.42M | -7.41M | -1.59M |
| Operating Cash Flow | -44.90M | -23.93M | -14.60M | -11.37M | -7.41M | -1.59M |
| Investing Cash Flow | -20.81M | -7.21M | -1.18M | -52.09K | 0 | -802 |
| Financing Cash Flow | 370.08M | 107.39M | 15.95M | 15.46M | 3.23M | 18.85M |
Immix Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMMX, the sentiment is Negative. The current price of 8.07 is below the 20-day moving average (MA) of 8.09, below the 50-day MA of 9.94, and below the 200-day MA of 9.61, indicating a bearish trend. The MACD of -0.42 indicates Negative momentum. The RSI at 44.49 is Neutral, neither overbought nor oversold. The STOCH value of 70.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMMX.
Immix Biopharma Risk Analysis
Immix Biopharma disclosed 61 risk factors in its most recent earnings report. Immix Biopharma reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksImmix Biopharma Peers Comparison
Overall Rating
- IMMX51Neutral
KURA48Neutral
CTMX47Neutral
ALLO46Neutral
FATE42Neutral
ARTV40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| IMMX | 51Neutral | $717.94M | -9.27 | -38.44% | ― | ― | -11.21% |
| KURA | 48Neutral | $710.22M | -2.26 | -336.24% | ― | -23.76% | -33.09% |
| CTMX | 47Neutral | $464.35M | -4.55 | -33.97% | ― | -87.66% | -210.45% |
| ALLO | 46Neutral | $311.86M | -1.33 | -49.84% | ― | ― | 36.37% |
| FATE | 42Neutral | $195.12M | -1.30 | -73.92% | ― | -33.45% | 21.90% |
| ARTV | 40Underperform | $201.19M | -1.32 | -45.32% | ― | ― | 7.78% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IMMX | Immix Biopharma, Inc. | 8.07 | 3.86 | 91.69% | |
| FATE | Fate Therapeutics Inc | 1.34 | 0.38 | 39.00% | |
| CTMX | CytomX Therapeutics Inc. | 2.04 | -1.84 | -47.42% | |
| KURA | Kura Oncology | 7.43 | -3.78 | -33.69% | |
| ALLO | Allogene Therapeutics | 0.83 | -0.40 | -32.76% | |
| ARTV | Artiva Biotherapeutics, Inc. | 3.96 | 0.71 | 21.85% |
Immix Biopharma Corporate Events
Immix Biopharma Prices $125 Million Equity Offering
PositiveOn September 29, 2026, Immix Biopharma priced an underwritten registered offering of 11,363,637 shares of common stock at $11.00 per share, implying gross proceeds of $125 million. The transaction, led by J.P. Morgan Securities with participation fro...
Immix Biopharma reports promising interim Phase 2 results
PositiveOn September 29, 2026, Immix Biopharma reported interim Phase 2 data from its fully enrolled, 45-patient NEXICART-2 trial in relapsed or refractory AL amyloidosis, showing that NXC-201 achieved an 89% complete response rate across all patients as ass...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026